**Press Release** **For Immediate Release**

## Glenmark confirms patent challenge for Bendamustine Hydrochloride

- This ANDA has been filed from Glenmark's Argentina lyophilized injectable facility

**December 31, 2013 :** Glenmark Pharmaceuticals Limited and Glenmark Generics Inc., USA ("Glenmark") confirms Cephalon Inc. has filed a patent infringement suit on 26 Dec 2013 in the U.S. District Court for the District of Delaware seeking to prevent Glenmark from commercializing its Abbreviated New Drug Application (ANDA) Bendamustine Hydrochloride product, their generic version of Treanda®, prior to expiration of the Orange Book patents. A complaint against Glenmark has been filed on US patent 8,445,524. This lawsuit was filed under the provisions of the Hatch-Waxman Act.

Bendamustine is indicated for the treatment of patients with Chronic Lymphocytic Leukemia. This ANDA has been filed from Glenmark's Argentina lyophilized injectable facility. For the twelve-month period ending September 2013, Treanda® achieved sales of USD 659 million according to IMS Health.

**About Glenmark Generics Limited**
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and developing an EU presence, which primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 80 countries, including the US, various countries in the EU, South America and India.

#####

**For further information, please contact:**
Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919/984
Email : connect@glenmark-generics.com